Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury

被引:66
作者
Abdallah, Y [1 ]
Gkatzoflia, A [1 ]
Pieper, H [1 ]
Zoga, E [1 ]
Walther, S [1 ]
Kasseckert, S [1 ]
Schäfer, M [1 ]
Schlüter, KD [1 ]
Piper, HM [1 ]
Schäfer, C [1 ]
机构
[1] Univ Giessen, Inst Physiol, D-35392 Giessen, Germany
关键词
reperfusion injury; cardiomyocytes; calcium; cGMP; sarcoplasmic reticulum;
D O I
10.1016/j.cardiores.2005.01.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Reperfusion injury of the myocardium is characterised by development of cardiomyocyte hypercontracture. Previous studies have shown that cGMP-mediated stimuli protect against reperfusion injury, but the cellular mechanism is Still unknown. Methods: To simulate ischemia/reperfusion, adult rat cardiomyocytes were incubated anoxically (pH(o) 6.4) and then reoxygenated (pH(o) 7.4). Cytosolic calcium [Ca2+](i) (fura-2 ratio), pH(i) (BCECF ratio), cell length, and phospholamban phosphorylation were analysed. Under simulated ischemia cardiomyocytes develop [Ca2+](i) overload. When reoxygenated they rapidly undergo hypercontracture, triggered by oscillations of [Ca2+](i). We investigated whether cGMP-rnediatcd stimuli can modulate [Ca2+](i) or pHi recovery and whether this contributes to their protective effect. Membrane-permeable cGMP analogues, 8-bromo-cGMP (1 mmol/L) or 8-pCPT-cGMP (10 mu mmol/L), or a receptor-mediated activator of particulate guanylyl cyclase, urodilatin (1 mu mol/L), were applied. Results: The investigated stimuli protect against reoxygenation-induced hypercontracture (cell length as percent of end-ischemic length; control: 68 +/- 1.6; 8-bromo-cGMP: 88 +/- 1.5*; 8-pCPT-cGMP: 84 +/- 2.9*; urodilatin: 87 +/- 1.1*; n=24; *p < 0.05). Recovery from [Ca2+](i) overload after 2 min reoxygenation [fura-2 ratio (a.u.); control: 1.43 +/- 0.15; 8-bromo-cGMP: 1.86 +/- 0.15*; 8-pCPT-cGMP: 1.92 +/- 0.19*; urodilatin: 1.93 +/- 0.24*; n=25; *p < 0.05] was accelerated, and the frequency of [Ca2+](i) oscillations (min(-1)) was significantly reduced (control: 49 +/- 5.0 min(-1); 8-bromo-cGMP: 18 +/- 3.5* min(-1); 8-pCPT-cGMP: 18 +/- 4.5* min(-1); urodilatin: 16 +/- 4.1* min(-1); n=24; *p < 0.05). cGMP-mediated stimuli increased sarcoplasmic Ca2+ sequestration (caffeine-releasable Ca2+ pool: 2-3 fold increase vs. control). Inhibition of sarcoplasmic Ca2+-ATPase (SERCA) by thapsigargin (150 nmol/L) or of protein kinase G with KT-5823 (1 mu mol/L) abolished the effect of these stimuli on [Ca2+](i) recovery. The investigated stimuli significantly enhanced phospholamban phosphorylation. Conclusions: We conclude that cGMP-dependent signals activate SERCA via a protein kinase G-dependent phosphorylation of phospholamban. The increase in SERCA activity seems to reduce peak [Ca2+](i) and [Ca2+](i) oscillation during reoxygenation and to attenuate the excessive activation of the contractile machinery that otherwise leads to the development of hypercontracture. (c) 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:123 / 131
页数:9
相关论文
共 26 条
  • [1] L-Arginine limits myocardial cell death secondary to hypoxia-reoxygenation by a cGMP-dependent mechanism
    Agulló, L
    García-Dorado, D
    Inserte, J
    Paniagua, A
    Pyrhonen, P
    Llevadot, J
    Soler-Soler, J
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (05): : H1574 - H1580
  • [2] Myocardial segment shrinkage during coronary reperfusion in situ - Relation to hypercontracture and myocardial necrosis
    Barrabes, JA
    GarciaDorado, D
    RuizMeana, M
    Piper, HM
    Solares, J
    Gonzalez, MA
    Oliveras, J
    Herrejon, MP
    Soler, JS
    [J]. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1996, 431 (04): : 519 - 526
  • [3] Becker BF, 2000, Z KARDIOL, V89, P88
  • [4] CANTILINA T, 1993, J BIOL CHEM, V268, P17018
  • [5] Sodium nitroprusside exacerbates myocardial ischemia-reperfusion injury
    Cope, JT
    Banks, D
    Laubach, VE
    Binns, OAR
    King, RC
    Richardson, RM
    Shockey, KS
    Tribble, CG
    Kron, IL
    [J]. ANNALS OF THORACIC SURGERY, 1997, 64 (06) : 1656 - 1659
  • [6] CORNWELL TL, 1991, MOL PHARMACOL, V40, P923
  • [7] Das S, 2002, DRUG EXP CLIN RES, V28, P213
  • [8] PHOSPHORYLATION SITE-SPECIFIC ANTIBODIES TO CARDIAC PHOSPHOLAMBAN
    DRAGO, GA
    COLYER, J
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (01) : S15 - S15
  • [10] GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440